trending Market Intelligence /marketintelligence/en/news-insights/trending/zfgk8p4ntovmrlmy0fbgtg2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Corcept Therapeutics plans $100M share buyback program

Blog

Global M&A Infographic Q1 2021

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge

Blog

COVID-19 Impact & Recovery: Private Equity

COVID-19 Impact & Recovery: Corporates


Corcept Therapeutics plans $100M share buyback program

Corcept Therapeutics Inc. said its board approved the repurchase of up to $100 million of the company's common stock.

The Menlo Park, Calif.-based pharmaceutical company said the share buyback program will remain in effect until June 30, 2019, unless terminated earlier.

Corcept added that the timing and amount of any repurchases will be based on market conditions, stock price and other factors.